39 active trials 25 recruiting 3 Phase 3 30 sponsors 5 changes in 30 days
| Phase 1 | 11 | |
| Phase 1/2 | 5 | |
| Phase 2 | 14 | |
| Phase 3 | 3 | |
| Phase 4 | 1 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT07264894 | ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a… | Zhengzhou University | Not Yet Recruiting | 2025-12-04 |
| Phase 3 | ||||
| NCT06496308 | Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment | Ruijin Hospital | Recruiting | 2024-07-11 |
| NCT07784101 | A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib… | Beijing InnoCare Pharma Tech Co., Ltd. | Not Yet Recruiting | 2026-08-25 |
| NCT04662255 | Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With… | Loxo Oncology, Inc. | Active, Not Recruiting | 2026-05-15 |
| Phase 2 | ||||
| NCT07272499 | Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With… | Ruijin Hospital | Recruiting | 2026-07-28 |
| NCT07082686 | A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or… | Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting | 2026-07-23 |
| NCT07719556 | Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With… | The First Affiliated Hospital with Nanjing Medical University | Recruiting | 2026-07-22 |
| NCT04792489 | DALY II USA/ MB-CART2019.1 for DLBCL | Miltenyi Biomedicine GmbH | Recruiting | 2026-07-13 |
| NCT07460362 | Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory… | Peking University Third Hospital | Recruiting | 2026-03-10 |
| NCT07077512 | Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma | Sun Yat-sen University | Recruiting | 2026-01-21 |
| NCT07285590 | Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in… | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Recruiting | 2025-12-16 |
| NCT07199296 | Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell… | Ruijin Hospital | Recruiting | 2025-09-30 |
| NCT06846489 | Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk… | Sun Yat-sen University | Recruiting | 2025-06-03 |
| NCT02213926 | An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell… | Acerta Pharma BV | Active, Not Recruiting | 2026-08-04 |
| NCT07684950 | Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After… | Henan Cancer Hospital | Not Yet Recruiting | 2026-07-06 |
| NCT05951959 | A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment… | AstraZeneca | Active, Not Recruiting | 2026-06-01 |
| NCT07569965 | Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in… | Miltenyi Biomedicine GmbH | Not Yet Recruiting | 2026-05-06 |
| NCT05716087 | A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma | Guangzhou Lupeng Pharmaceutical Company LTD. | Active, Not Recruiting | 2026-01-15 |
| Phase 1/2 | ||||
| NCT07788118 | A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell… | Second Affiliated Hospital, Zhejiang University, School of Medicine | Recruiting | 2026-08-26 |
| NCT07609862 | A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies | Guangzhou Lupeng Pharmaceutical Company LTD. | Recruiting | 2026-07-30 |
| NCT04186520 | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies | Medical College of Wisconsin | Recruiting | 2026-02-23 |
| NCT05471843 | Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell… | BeiGene | Active, Not Recruiting | 2025-09-09 |
| NCT03153202 | Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in… | Joshua Brody | Active, Not Recruiting | 2024-11-19 |
| Phase 1 | ||||
| NCT06980116 | Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell… | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Recruiting | 2026-08-13 |
| NCT07424833 | A Study of APG-3288 in Relapsed/Refractory Blood Cancers | Ascentage Pharma Group Inc. | Recruiting | 2026-07-30 |
Ruijin Hospital (3) · Acerta Pharma BV (2) · Beijing InnoCare Pharma Tech Co., Ltd. (2) · Guangzhou Lupeng Pharmaceutical Company LTD. (2) · Miltenyi Biomedicine GmbH (2) · Nurix Therapeutics, Inc. (2) · Peking University Third Hospital (2) · Sun Yat-sen University (2) · Ascentage Pharma Group Inc. (1) · AstraZeneca (1)